Side-by-side comparison of AI visibility scores, market position, and capabilities
Leading single-cell genomics platform; $642M FY2025 revenue. Chromium and Visium spatial platforms power cell-type discovery in oncology, neuroscience, and immunology.
10x Genomics was founded in 2012 in Pleasanton, California by Serge Saxonov, Ben Hindson, and Kevin Ness. The company developed the Chromium platform for single-cell RNA sequencing (scRNA-seq), enabling researchers to analyze gene expression across thousands of individual cells simultaneously—a capability that transformed cell biology, immunology, and cancer research. The Visium Spatial Gene Expression platform extended this to map gene expression within intact tissue architecture.\n\n10x Genomics' instruments and consumables are used by leading academic research centers, pharmaceutical companies, and translational medicine teams to profile the cellular composition of tumors, map the nervous system, characterize immune responses, and develop cell therapies. The company reported full-year 2025 revenue of $642.8 million, up from $610.8 million in 2024, and guides to $600–$625 million for 2026 amid cautious biotech funding conditions.\n\nThe company is transitioning toward a broader multi-omics portfolio including ATAC-seq, protein detection, and spatial multi-omics, while defending market position against competition from Parse Biosciences, Vizgen, and others. Despite near-term funding headwinds in academic markets, 10x Genomics remains a foundational infrastructure provider for the cell atlas era of biology.
Dotmatics (acquired by Insightful Science 2024) serves 1M+ researchers at 10,000+ organizations; R&D data management and scientific informatics platform spanning drug discovery to bioprocessing.
Dotmatics is a scientific R&D software company providing data management, informatics, and collaboration tools for researchers in pharmaceutical, biotechnology, agrochemical, and academic institutions. The company's platform connects experimental data, scientific protocols, lab notebooks, and analytical results across the drug discovery and development workflow, enabling research teams to find, share, and build on each other's work at scale.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.